Nanoformulation makes a wide range of drugs more stable, controllable with lower preparation costs
|
Categories |
Nanodispersion, pharmacology, liposphere, liphophilic drug, concentrated pre-dispersion, amphotericin B |
|
Development Stage |
Concept proven with cyclosporine and amphotericin B |
|
Patent Status |
Patent pending |
|
Market Size |
$60B |
Highlights
-
Replaces highly toxic, complicated and expensive infusion formulations
-
Easy preparation and scale-up
-
Works with oral, topical and IV pharmacological agents
-
Extended release from a few hours to several days of entrapped drug after a single injection
Our Innovation
-
Developed concentrated nano-formulations for improved bioavailability of lipophilic drugs
-
Better physical stability
-
Low cost of ingredients
-
High dispersability in an aqueous medium
-
High entrapment of hydrophobic drugs
The Opportunity
-
Alternative formulations for existing marketed drugs for faster absorption or clear soft gelatin capsules
-
Provides controlled delivery of a wide range of drugs including but not exclusive to anti-inflammatory compounds, local anesthetics, antibiotics, anticancer agents, vaccines, adjuvants, and peptides
-
Allows oral formulation of drugs previously only administered IV or by infusion
1586128900.png)